<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47985">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02481518</url>
  </required_header>
  <id_info>
    <org_study_id>2558/172</org_study_id>
    <nct_id>NCT02481518</nct_id>
  </id_info>
  <brief_title>Preloading Magnesium Attenuate Cisplatin-induced Nephrotoxicity</brief_title>
  <acronym>PRAGMATIC</acronym>
  <official_title>Preloading Magnesium Attenuate Cisplatin-induced Nephrotoxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether magnesium preloading reduce incident of
      cisplatin induced acute kidney injury in head and neck cancer who receiving low dose
      cisplatin (40 mg/m2 weekly for 7 weeks).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized controlled trial comparing efficacy of magnesium preloading versus normal saline
      for prevention of acute and chronic nephrotoxicity of cisplatin.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Participant, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>7 days after cisplatin administration</time_frame>
    <description>Comparing serum creatinine before Cisplatin treatment and seven days after cisplatin treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nephrotoxicity</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Compare serum creatinine before Cisplatin treatment and complete 7 cycles of cisplatin treatment ( up to 12 weeks)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Magnesium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnesium preloading group : Magnesium preloading for Cisplatin treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group : Normal saline preloading for cisplatin treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium</intervention_name>
    <description>Pre loading fluid with Magnesium sulphate 16 milliequivalent plus potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration</description>
    <arm_group_label>Magnesium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Eastern Cooperative Oncology Group score 0-2

          -  First Diagnosed Head and neck cancer and plan for treatment with cisplatin

          -  Serum creatinine ≤1.5 mg/dl or eGFR≥60(ml/min/1.73 m2)

        Exclusion Criteria:

          -  Prior treatment with cisplatin before randomization

          -  Uncontrolled concurrent disease

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arkom Nongnuch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ramathibodi hospital, Mahidol university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arkom Nongnuch, MD</last_name>
    <phone>+6622011400</phone>
    <email>oatega@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ramathibodi hospital, Mahidol university</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arkom Nongnuch, MD</last_name>
      <phone>+6622011400</phone>
      <email>oatega@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Arkom Nongnuch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>May 17, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cisplatin nephrotoxicity</keyword>
  <keyword>Acute kidney injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
